AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04446624 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music therapy intervention
Description: Group psychotherapy with music intervention
Study NCT02018848 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Attention Training Program
Study NCT04793724 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Simeox
Description: A respiratory physiotherapy session with the Simeox device will be performed in accordance with the official PhysioAssist recommendations, which are;~* clearance of the upper airways before the physiotherapy session~* correct position of the mouthpiece in patient's mouth, with the lips placed on the thinnest part of the mouthpiece and the tongue positioned underneath the mouthpiece~* slow nasal inhalation without too much recruitment of the inspiratory residual volume (IRV) and an exhalation with real deflation of the thorax~* step-by-step shifting of the patient's tidal volume towards the expiratory residual volume (ERV), in order to target the most distal regions of the lungs~* comfortable, relaxed sitting position with straightened spine~* controlled cough, which will be encouraged only when it is productive
Study NCT04793724 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PARI O PEP
Description: ACT with PARI O-PEP will be performed in an upright sitting position, using four positions of the device for the most effective clearance of mucus from the lungs. These positions will be:~* horizontal;~* low;~* transition of the device from the low position to the horizontal position;~* upside down.~The mouthpiece will be placed between the patient's teeth as per standard procedure, and enclosed properly within the lips. Patients will perform slow and deep inhalation via the nose, then hold their breath for about 1 to 2 seconds at the end of inhalation. Exhalation will be performed slowly and completely into the PARI O-PEP through the patient's mouth. At the end of the session, the patient will perform huffing with the PARI O-PEP device in the upside down position in order to maintain open airways, and, if possible, expectoration sputum.
Study NCT02339142 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External beam radiotherapy
Description: 100 Rads to each lateral orbit x 10 doses
Study NCT02339142 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intravenous corticosteroids (methylprednisolone)
Description: Intravenous methylprednisolone (iv MP) 500 mg weekly x 6 weeks, then iv MP 250 mg x 6 weeks
Study NCT02339142 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intravenous corticosteroids (methylprednisolone)
Description: Intravenous methylprednisolone (iv MP) 500 mg weekly x 6 weeks, then iv MP 250 mg x 6 weeks
Study NCT00675623 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dimebon
Description: Dimebon, 5 mg orally three times daily for six months
Study NCT00675623 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dimebon
Description: Dimebon 20 mg orally three times daily for six months
Study NCT00675623 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo three times daily for six months
Study NCT04361409 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375mg/m2 on Day-14 and Day-7
Study NCT04361409 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 70mg/m2 on Day1
Study NCT04361409 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1000mg/m2 on Day8
Study NCT04652206 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCO-101
Description: Oral tablets with a strength of 50 mg or 150 mg according to dose level (cohort). Administered for 6 consequtive days in a bi-weekly schedule in each treatment cycle. Treatment until disease progression.
Study NCT04652206 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Used according to marketing authorisation
Study NCT04652206 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab paclitaxel
Description: Used according to marketing authorisation
Study NCT02446249 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AAV2hAQP1
Description: Infusion of gene therapy
Study NCT03110978 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study NCT03110978 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: Undergo stereotactic body radiation therapy
Study NCT01733862 — intervention group
Intervention type: OTHER
Intervention: Data collection
Description: Data sheet. Data will be collected and is planned to be analysed at the following time points:~Pre-vaccination period: Nov 2007 to Oct 2011, transition period: Nov 2011 to Oct 2012 and post vaccination period: Nov 2012 to Oct 2016.
Study NCT03192280 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leukotriene B4
Description: Leukotriene B4 (LTB4)
Study NCT03192280 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FLIR One
Description: Thermal imaging attachment to iPhone
Study NCT01918683 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: TACE transarterial chemoembolization
Study NCT01918683 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: TACE transarterial chemoembolization
Study NCT01918683 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: stereotatic body radiotherapy (SBRT)
Study NCT03489824 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: modified- WIM colonoscopy
Description: Modified-water immersion method of colonoscopy refers to the freely episodic suction of the infused-water during colonoscopy insertion phase at a moment to negotiate the angulated colon to facilitate cecal intubation but not suction the mucosa. The original water immersion method only suctions the water when the colon is over-distended or it is dirty and exchanges it with the new cleans water during insertion then evacuates all of the water during withdrawal
Study NCT03489824 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: modified- WIM colonoscopy
Description: Modified-water immersion method of colonoscopy refers to the freely episodic suction of the infused-water during colonoscopy insertion phase at a moment to negotiate the angulated colon to facilitate cecal intubation but not suction the mucosa. The original water immersion method only suctions the water when the colon is over-distended or it is dirty and exchanges it with the new cleans water during insertion then evacuates all of the water during withdrawal
Study NCT03580694 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN4659
Description: REGN4659 will be administered by intravenous (IV) infusion.
Study NCT03580694 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cemiplimab
Description: Cemiplimab will be administered by intravenous (IV) infusion.
Study NCT03859349 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Selective Targeted Sampling
Description: After CLNS assessment, patients with proven malignant mediastinal lymph nodes will be referred for chemoradiation and patients with proven benign mediastinal lymph nodes will undergo surgical resection as per standard of care guidelines. Final pathology from the resected specimen will be considered the gold standard for analysis of sensitivity and specificity.
Study NCT03859349 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Systematic Sampling
Description: Following routine biopsy of lymph nodes, patients with proven malignant mediastinal lymph nodes will be referred for chemoradiation and patients with proven benign mediastinal lymph nodes will undergo surgical resection as per standard of care guidelines. Final pathology from the resected specimen will be considered the gold standard for analysis of sensitivity and specificity.
Study NCT00450684 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implantation and testing of CRT
Description: Biventricular pacing for 12 weeks (CRT ON) followed by automatic rhythmicity or the original, conventional biventricular stimulation for 12 weeks (CRT OFF), then returning to biventricular pacing (CRT ON).
Study NCT00450684 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implantation and testing of CRT
Description: Automatic rhythmicity or original conventional biventricular stimulation for 12 weeks (CRT OFF) followed by biventricular pacing (CRT ON).
Study NCT03519646 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eliglustat
Description: 1. This is a 3-year study and the enrollment time of this study is 24 months.~2. The participants have to receive the investigational agent, Cerdelga~3. The participants have to go back to the hospital and receive the investigational agent and take the test before receving Cerdelga, and 2 weeks, 1, 3, 6, 12, 18 and 24 months after receiving Cerdelga.~4. IMP Administration Method: Cerdelga have 21 mg、42 mg and 84 mg capsule.~5. No need for fasting before use, but can't take with grapefruit juice.~6. Five ml Blood and 10 ml urine shoud be taken before receiving Cerdelga, and 1, 3, 6, 12, 18 and 24 months after receiving Cerdelga for Gaucher related biomarkers test.
Study NCT01310101 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ofatumumab plus dexamethasone
Description: Dose and schedule~Cycle 1:~Ofatumumab: 300 mg as an i.v. infusion on day 1 of the cycle; Ofatumumab: 2000 mg as an i.v. infusion on days 8, 15, 22; Dexamethasone: 40 mg/day p.o., days 1-4 and 15-18~Cycles 2 to 6 (cycles every 28 days):~Ofatumumab: 1000 mg i.v. infusion on day 1, 8, 15 and 22 of the cycle; Dexamethasone: 40 mg/day p.o., days 1-4 and 15-18
Study NCT04581161 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Life2000® Ventilator
Description: POV support (Life2000) will be administered in six (6) to ten (ten) enrolled subjects based on clinical protocol flowchart (Appendix C). Specifically, if it is determined that a COVID-19 subject who would currently be considered for HFNC under current standard of treatment, will be eligible for POV treatment.~The prescribed therapy regimen, including duration of therapy will be documented and COVID-19 patients who fail therapy and require IMV will be recorded.
Study NCT03657511 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Educational Interventions to Promote Tobacco Cessation
Description: Women receiving a screening mammogram at KCI downtown and McLaren Macomb, will be given a self-administered questionnaire at check-in.~Women who indicate they are current smokers are eligible for the study. After the screening mammogram is complete, eligible women will be consented. Educational materials will be provided to the participant at that time. The materials provided outline evidence-based approaches to smoking cessation and include contact information for local resources including cessation support groups, Michigan Tobacco Quitline, American Cancer Society's Guide to Quitting Smoking, Quitnet, Smokfree.gov and Become An Ex. The participant will be contacted by telephone approximately 12 weeks later to determine if she is currently smoking or had quit in the last 12 weeks.
Study NCT01918930 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MGA271
Description: MGA271 anti-B7-H3 monoclonal antibody
Study NCT03630952 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 0.5 mg Conbercept Intravitreal Injection
Description: Subjects received 0.5 mg conbercept intravitreal injection at Day 1, Week 4 and Week 8 (three injection loading dose), and treated every eight weeks thereafter (0.5 mg, q8w) through Week 36. At the Week 40 visit, the criteria-based pro re nata (PRN) approach will begin through the end of the treatment period at Week 92, for a total of 92 weeks treatment in the study eye.
Study NCT03630952 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 1.0 mg Conbercept Intravitreal Injection
Description: Subjects received 1.0 mg conbercept intravitreal injection at Day 1, Week 4 and Week 8 (three injection loading dose), and treated every twelve weeks thereafter (1.0 mg, q12w) through Week 36. At the Week 40 visit, the criteria-based PRN approach will begin through the end of the treatment period at Week 92, for a total of 92 weeks treatment in the study eye.
Study NCT03630952 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 2.0 mg Aflibercept Intravitreal Injection
Description: Subjects received 2.0 mg aflibercept intravitreal injection at Day 1, Week 4 and Week 8 (three injection loading dose), and treated every eight weeks thereafter (2.0 mg, q8w) through Week 36. At the Week 40 visit, the criteria-based PRN approach will begin through the end of the treatment period at Week 92, for a total of 92 weeks treatment in the study eye.
Study NCT03748147 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: prostaglandin e1
Study NCT03192280 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SCIO
Description: Handheld near-IR molecular spectroscopy device
Study NCT03192280 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MS Band 2
Description: Wearable watch-like device with multiple sensors
Study NCT03192280 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AGE reader
Description: Portable bench top device for in-clinic near UV assessment
Study NCT03192280 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HSI prototype (PARC) hyper-spectral camera
Description: Portable bench top device for in-clinic multispectral imaging
Study NCT03192280 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iPhone 7
Description: Smart phone
Study NCT04451226 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fezolinetant
Description: Oral
Study NCT03748147 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol
Description: prostaglandin e1
Study NCT01115725 — intervention group
Intervention type: DRUG
Intervention: Gonal-f® (follitropin alfa)
Description: Gonal-f® (follitropin alfa) will be given once daily subcutaneously at a starting dose of 150-375 international unit per day (IU/day) by self-administered injection via a pen device for first 5 days. After Day 5, Gonal-f® dose will be adjusted according to the investigator's discretion until ovarian response observed.
Study NCT03259776 — intervention group
Intervention type: OTHER
Intervention: Qualitative interviews and questionnaire survey
Description: Qualitative interviews and questionnaire survey
Study NCT02785029 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OCT
Study NCT03933137 — intervention group
Intervention type: OTHER
Intervention: Portsmouth Physiological and Operative Severity Score for the Enumeration of Mortality and Morbidity (P-POSSUM) score
Description: P-POSSUM score's variables are divided into physiological parameters (age, cardiac, respiratory, ECG, systolic blood pressure, pulse rate, haemoglobin, leukocyte count, urea, sodium plasma, potassium plasma, and GCS) and operative parameters (operation type, number of procedures, operative blood loss, peritoneal contamination, malignancy status, CEPOD).
Study NCT00732966 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: losartan
Description: with losartan 50 mg once daily for one month
Study NCT02697981 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: nutrition counseling
Description: nutrition counseling and guidance.
Study NCT01071252 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AIN457
Study NCT00732966 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: valsartan
Description: valsartan 160 mg once daily
Study NCT00090519 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ruboxistaurin
Description: 32 mg once daily (QD) oral for up to 36 months
Study NCT00090519 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: QD oral for up to 36 months
Study NCT02645942 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L-carnitine
Description: L-carnitine 1400 mg daily for 8 weeks
Study NCT02645942 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo daily for 8 weeks
Study NCT00694889 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neuroadaptive cognitive training
Description: Neuroadaptive cognitive training includes cognitive remediation exercises that participants will practice 1 hour per day, 5 days per week, for 8 weeks. The exercises are specifically designed to improve speed and accuracy in the perception of and response to verbal targets. The treatment will focus on TCT.
Study NCT01071252 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT05023291 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Positron Emissie Tomografie - Computer Tomografie
Description: In this study, the high-resolution PET-CT system will be used to evaluate the cutting edges after tumor resection. The goal is to evaluate the distance of the tumor cells from the cutting edges of the surgical piece. The patient receives an intravenous injection of radiolabeled sugar (18F-FDG). 18F-FDG is the standard PET tracer for diagnostic PET-CT research. This standard dose will always be calculated according to the formula: 3.7 x body weight + 37 Mbq.
Study NCT00204594 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rM28
Study NCT00204594 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: autologous PBMCs
Study NCT03333252 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention Condition
Description: Caregivers will access caregiving related information. Care Recipients will access cognitive training program
Study NCT03333252 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control Condition
Description: Caregivers will access Nutrition and Health Promotion material. Care Recipients will access words and card games
Study NCT02793349 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Absorb Bioresorbable Vascular Scaffold
Description: Absorb Bioresorbable Vascular Scaffold
Study NCT03621176 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home-based exercise
Description: A booklet with detailed information will be provided, and the exercises will be previously reviewed with every patient by the researcher. Participants will be encouraged to perform at least 3 sessions per week and monitor their heart rate. They will be instructed that the exercises should be perceived as 'somewhat hard' from a rate of perceived exertion. Adaptations to increase the intensity of the exercises will be provided so that participants can progress in exercise intensity
Study NCT04105348 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: HbA1c
Description: patients with raised investigations will be included in group 1 patients with normal investigations will be included in group 2
Study NCT01551680 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation combined with iniparib (BSI-201)
Description: Dose escalation of iniparib is implemented according to the CRML method. Three patients will be included at the first dose level (2.8 mg/kg). As long as no DLT is observed, escalation will proceed in cohorts of three patients at least included at the next dose levels (4, 5.6, 8, 11.2 mg/kg). Once a DLT is observed, the CRML will be activated and will be used until the MTD has been found or until six patients have been treated at the highest dose level (11.2 mg/kg). A dose level of 2.0 mg/kg (dose level -1) is included in case the first dose level at 2.8 mg/kg is found to be the MTD.~Iniparib is given by iv infusion over 1 hour twice weekly. BSI 201 will start the week before the beginning of radiotherapy (W1) and will be continued during the entire irradiation (W2, W3, W4). It will be stopped after 8 injections.~RT is delivered five days a week over 3 weeks (W2, W3, W4) up to a total dose of 37.5 Gy. Each fraction delivers 2.5 Gy by two opposed tangential fields.
Study NCT02494518 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Forced Exercise & Upper Extremity Repetitive Task Practice
Study NCT02494518 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Voluntary Exercise & Upper Extremity Repetitive Task Practice
Study NCT02494518 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stroke Education & Upper Extremity Repetitive Task Practice
Study NCT01377155 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Insulin detemir
Description: Subjects will be randomized to weight based method of 0.1 U/kg for basal insulin or a starting dose based upon an insulin challenge. Subject will record morning fasting blood sugar daily. Using a three day average, the subject will titrate the dose of basal insulin either increasing or lowering by three units based upon target blood glucose of 110 mg/dl.
Study NCT02724917 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APN1125
Description: Oral solid dose form of APN1125
Study NCT02724917 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to match
Study NCT02662504 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: photodynamic therapy (PDT)
Description: Intra-operative (intrapleural) photodynamic therapy (PDT): briefly, each patient will receive porfimer sodium (PHOTOFRIN®) (2 mg/kg) 24 hours before eP/D (IV injection on 3-5 minutes). Cutaneous light precautions will be instituted immediately and for the next 4 weeks.~After complete macroscopic resection of the tumour, the thoracic surgeon and his team will set isoprobes (7 at least) in the pleural cavity to monitor by a dosimetry device the correct illumination of the cavity with a visible red light (wavelength of 630 nm; laser source). PDT-related postoperative considerations include light precautions, intensive focus on perioperative nutrition, and a greater than normal fluid requirement in the immediate postoperative period.